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The aim of this study was to determine whether inhibition of resistin by a synthetic antiresistin RNA (oligonucleotide) oligo
ameliorates metabolic and histological abnormalities in nonalcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD)
in mice. The antiresistin RNA oligo and a scrambled control oligo (25mg/kg of body weight) were i.p. injected to HFD mice.
Serum metabolic parameters and hepatic enzymes were measured after 4-week treatment. The treatment significantly reduced
epididymal fat and attenuated the elevated serum resistin, cholesterol, triglycerides, glucose, and insulin with an improved glucose
tolerance test. Antiresistin RNA oligo also normalized serum AST and ALT levels with improved pathohistology of NAFLD.
Immunoblotting and qRT-PCR revealed that decreased protein andmRNAexpression of resistin in fat and liver tissues of the treated
mice were associated with reduction of adipose TNF-𝛼 and IL-6 expression and secretion into circulation. mRNA and protein
expression of hepatic phosphoenolpyruvate carboxykinase (PEPCK) and sterol regulatory element-binding protein-1c (SREBP-1c)
were also significantly decreased in the treatedmice.Our results suggest that resistinmay exacerbateNAFLD inmetabolic syndrome
through upregulating inflammatory cytokines and hepatic PEPCK and SREBP-1c. Antiresistin RNA oligo ameliorated metabolic
abnormalities and histopathology of NAFLD through attenuating proinflammatory cytokines.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is emerging as
an important public health problem worldwide. NAFLD is
classified from the range of simple steatosis and nonalcoholic
steatohepatitis (NASH) followed by fibrosis [1]. The pathol-
ogy of NAFLD is characterized by excessive deposition of
free fatty acids (FFAs) and triglycerides (TG) in the hepatic
parenchyma [2]. NAFLD is a multifactorial disease coupled
with clinical hallmarks ofmetabolic syndrome (MetS) includ-
ing obesity, insulin resistance, dyslipidemia, and lower grade
inflammation [3]. Recently, increased prevalence of NAFLD
has been reported in patients with MetS and polycystic
ovary syndrome (PCOS) [4, 5], suggesting that the devel-
opment of NAFLD, PCOS, and MetS shares some common
pathogenesis, for example, central obesity with increased
adipocyte-derived cytokines and inflammatory processes [6,
7]. Increased evidence indicates that excessive abdominal fat
associated with ectopic fat deposition in nonadipose tissues
exacerbates inflammation and lipotoxicity through releasing
various adipose-derived proteins, termed “adipokines,” into
the circulation, leading to MetS and NAFLD [3, 8].
Of the identified adipose-derived adipokines, resistin
seems to assert its effects on both inflammatory and insulin
signalling pathways [9]. Resistin was originally discovered
in the adipose tissue of mice and named for its ability to
resist (interfere with) insulin action [10]. Animal studies have
highlighted the ability of resistin to induce skeletal muscle
and hepatic insulin resistance after both acute and chronic
administration [11, 12]. Increasing evidence from clinical
studies suggests that resistin is implicated in various human
pathologies, including MetS, type 2 diabetes, cardiovascular
disease [CVD], and obesity-related subclinical inflammation
[13–16], but the role of resistin in the development of NAFLD
is controversial. A few clinical studies have reported that
serum resistin levels did not differ between patients with
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NAFLD and without the disease [17]. However, one study
has shown that excessive ectopic accumulation of fat in
the liver and skeletal muscle of insulin-resistant subjects is
associated with lower concentrations of serum resistin [18],
while another reports increased levels of circulating resistin,
but only in patients with severe liver disease [19]. These
inconsistent findings indicate that the role of resistin in
NAFLD should be further clarified.
The pathogenesis of NAFLD is positively correlated to
overnutrition or inappropriate diet which leads to chronic
elevated circulating glucose, insulin, and FFA [20]. Our
previous studies have demonstrated that high-fat diet (HFD)
induces metabolic syndrome accompanied by an increased
accumulation of TG in the liver of rats and mice [21, 22].
Another study has shown that HFD-induced obesity in
rodents is associated with the elevation of serum resistin
levels and hepatic insulin resistance [23]. However, it remains
to be elucidated as to whether increased resistin expression
and secretion are directly implicated in NAFLD. Unlike
murine resistin, resistin is mainly secreted bymacrophages in
humans [24], suggesting that resistin is linked to inflamma-
tion which is crucial in the pathogenesis of NAFLD [25]. The
illustration of this relationship between resistin expression
and elevated proinflammatory cytokines, such as tumor
necrosis factor-𝛼 (TNF-𝛼) and interleukins (ILs), will help
to understand the pathogenesis of NAFLD. Furthermore,
whether overexpression of resistin is involved in abnormal
hepatic de novo lipogenesis remains unclear. In the present
study, a synthetic RNA oligonucleotide (oligo) was designed
to target the mouse resistin gene (antiresistin RNA oligo) as
a pharmacological tool to clarify the actual role of resistin
in HFD-induced NAFLD in mice. Furthermore, whether
inhibition of resistin with antiresistin RNA oligo ameliorates
HFD-induced metabolic syndrome and NAFLD and the
possible molecular mechanisms were investigated.
2. Material and Methods
2.1. Design of RNA Oligonucleotide (Oligo) against Resistin
mRNA. RNA oligo was designed to complement the
start codon region of the mouse resistin gene (GenBank:
AF323080.1) along the resistin mRNA based on the free
energy analysis. The RNA oligo was modified with 2󸀠-
O-methyl and a 3󸀠-butanol cap to increase the in vivo
stability of RNA.The sequences of RNA oligo against resistin
(antiresistin oligo) and the scrambled control RNA oligo
(control oligo) were 5󸀠-GGG AAA UGA AAG GUU CUU
CAU-3󸀠 and 5󸀠-AGA CCU CUC AUA GCA GCU GAT-3󸀠,
respectively. To validate synthetic RNA oligo could effectively
block resistin expression, antiresistin oligo and the control
oligo were transfected into 3T3-L1 adipocytes. The efficiency
of synthetic RNA oligo to block resistin expression in
transfected 3T3-L1 cell was 97% determined by quantitative
real-time polymerase chain reactions (qRT-PCR) assay as
described previously [22].
2.2. Animals and Treatment. Male C57BL/6 mice (8 weeks of
age with average body weight 20.87 g) supplied by the Animal
Resources Center (Perth, Australia) were acclimatized in
communal cages at 22∘C, with a 12 h light, 12 h dark cycle
(lights on at 0700) for 1 week and had access to a standard
chow or a HFD (59% fat, 21% protein, and 20% carbohydrate
by energy composition) for 10 weeks to induce insulin
resistance and fatty liver disease. Bodyweight and food intake
were measured weekly. Antiresistin RNA oligo and control
oligo were freshly prepared in medical saline at the ratio of
25mg per 5mL. The treatment dosage and its duration were
designed to ensure the maximal stable inhibition of the gene
transcript of interest, which was derived from our previous
study [22]. After 10-week HFD feeding, HFD mice were
randomly divided into two groups (𝑛 = 10) and treated with
scrambled control oligo (25mg/kg of body weight) or antire-
sistin oligo (25mg/kg of body weight) via i.p. injection every
second day for 4 weeks. HFD feeding was continued during 4
weeks of treatment. 10 chow fedmice were treated with saline
(5mL/kg of body weight) i.p. injection as a normal control
group to HFD fed mice with the control oligo treatment.
All experimental procedures were approved by the Joint
RoyalNorth ShoreHospital/University of Technology Sydney
Animal Care and Ethics Committee and were in accordance
with the National Health and Medical Research Council of
Australia Guidelines on Animal Experimentation.
2.3. Intraperitoneal Glucose Tolerance Tests. At the end of 4
weeks’ treatment, all mice were subjected to the intraperi-
toneal glucose tolerance test (i.p.GTT) following an overnight
fasting (12 hours). A glucose bolus (2 g/kg of body weight)
was i.p. injected to the conscious, unrestrained mice. The
blood glucose levels were determined from tail blood samples
taken at 0 (prior to glucose administration), 15, 30, 60, 90,
120, and 150min after the glucose injection using One Touch
Profile glucometer. Results of i.p.GTT were expressed as
integrated areas under the curves (AUC) over 150min for
glucose calculated using the Trapezoidal Rule with Graphpad
prism 4 software (Graphpad Prism, CA, USA).
2.4. Blood and Tissue Sample Collection. At the end of the
experiment, mice were fasted overnight (12 hours) and then
deeply anaesthetized with inhalant aesthetic gas (isoflurane
and nitrous oxide). Blood samples were collected from the
heart and centrifuged (10min at 1400 g) to separate the serum
fraction for biochemistry assays. Liver and visceral adipose
tissue were quickly excised and then stored at −80∘C for later
measurements.
2.5. Measurement of Metabolic Parameters. Fasting serum
total cholesterols, TG, and nonesterified fatty acids (NEFAs)
were analysed using enzymatic colorimetric kits obtained
from Roche Diagnostics GmbH (Mannheim, Germany) and
Wako Pure Chemical Industries (Osaka, Japan), respec-
tively. Fasting serum insulin concentration was measured
using ELISA kits (Linco Diagnostic Services, MO, USA).
Fasting serum glucose, ALT, and AST were determined by
spectrophotometric analysis using commercial kits (Dialab,
Vienna, Austria). Hepatic TG was determined from liver tis-
sue extraction using the chloroform/methanol method (2 : 1)
described previously [16]. Whole-body insulin sensitivity
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was estimated according to the homeostasis model assess-
ment of insulin resistance (HOMA-IR) using the formula:
[fasting serum glucose (mmol) times fasting serum insulin
(mU/mL)]/22.5.
2.6. Liver Histological Analysis. A small portion of frozen
liver tissue (𝑛 = 10) was cut and embedded with precooled
optimal cutting compound (Torrance, CA, USA) for cryostat
sectioning at 6 𝜇m. The sections were mounted on micro-
scope slides then fixed with 10% formaldehyde solution. The
samples were then stained with Haematoxylin and Eosin
(H&E) or Oil Red O (Sigma-Aldrich, St. Louis, MO, USA).
H&E-stained slides were observed under light microscopy
(Olympus, BX51 microscope, Tokyo, Japan) to investigate the
architecture of liver and hepatocyte steatosis. Images were
captured using an Olympus digital camera (DP70, Tokyo,
Japan) with a sample size at least 80 fields per group (original
magnification, ×400, 36-bit colour, 1280 × 1024 pixels). Liver
steatosis was graded with semiquantitative estimation of
the percentage of lipid-laden hepatocytes, according to the
method previously described [18]. At least 5 different high-
power fields (original magnification, ×400) were graded in a
blindedway. StainedOil RedO slides were visualizedwith the
Olympus microscope and images were captured with digital
camera (DP70, Tokyo, Japan) using Image-Pro 6.2 software
(Media Cybernetics, Inc., MD, USA).
2.7. Measurement of Resistin and Proinflammatory Cytokines
in Circulation. Serum resistin concentrations weremeasured
by a commercial ELISA kit (BD Biosciences, NSW, Australia)
according to the manufacturer’s instructions. Serum anal-
ysis of adiponectin was based on a commercially available
mouse adiponectin ELISA kit (EZMADP-60K; Millipore,
MO,USA). Serum levels of TNF-𝛼, interleukins (IL-6 and IL-
10), interferon gamma (IFN𝛾), and leptinweremeasuredwith
a standard sandwich enzyme immunoassay method using
the Bio-Plex Pro mouse cytokine assay kit (Bio-Rad Labora-
tories, Hercules, CA, USA) according to the manufacturer’s
instructions. Resulting levels of TNF-𝛼, ILs, IFN𝛾, leptin,
and adiponectin were determined using a Bio-Plex MAGPIX
array reader, which identified and quantified each specific
reaction based on bead colour and fluorescent signal intensity
and expressed as pictogram per millilitre.
2.8. Quantitative RT-PCR Assay of mRNA Expressions in
Adipose Tissue and Liver. The expression of mRNAs for
resistin, the proinflammatory cytokines (TNF-𝛼 and IL-6),
leptin, adiponectin in adipose tissue, TNF-𝛼, IL-6, PEPCK,
and SREBP-1c in the liver were determined by quantitative
real-time polymerase chain reactions (qRT-PCR). Total RNA
was extracted from 100mg of frozen visceral fat or liver
tissue of mice using TRIzol reagent (Invitrogen, Mulgrave,
VIC, Australia) according to the manufacturer’s protocol.
After determination of RNA concentrations by measuring
the absorbance at 260/280 nm 0.5 𝜇g RNA as template was
reversely transcribed to cDNA by using QuantiTect Reverse
Transcription kit (QIANGEN, Alabama, USA). cDNA was
amplified using PCR assay with the mouse primer sequences
listed in Table 1 (Sigma, CT, USA).
𝛽-actin was used as reference genes from Promega
(Madison, WI, USA). The amplification was performed with
fastStart Universal SYBR Green Master (Roche Diagnostics,
Mannheim, Germany) in Mastercycler ep realplex (Eppen-
dorf, CA,USA).The relativemRNA levels in antiresistin oligo
treated mice were presented as a percentage of mRNA levels
in control oligo group.
2.9. Immunoblotting Assays. Expressions of resistin protein
in adipose and liver tissues as well as hepatic PEPCK and
SREBP-1c were detected by immunoblot analysis. 100mg
of frozen liver or visceral fat samples was homogenized
in 1mL lysis buffer (Roche Diagnostics, Indianapolis, IN,
USA). Then, the homogenates were centrifuged at 3000×g
for 10min at 4∘C. The supernatants were collected and
the protein concentration of each supernatant was deter-
mined by the Bradford method. Total protein (20 𝜇g) was
separated to SDS-PAGE (4–20%) and electroblotted onto
PVDF membranes. Blotted membranes were blocked with
5% skim milk in PBS with 0.05% Tween 20 and incubated
with monoclonal antiresistin diluted at 1 : 3000 (ALEXIS
Biochemicals, San Diego, CA, USA), anti-PEPCK diluted at
1 : 1000 (Agrisera, Vannas, Sweden), anti-SREBP-1c, and anti-
𝛽-actin diluted at 1 : 1000 (SC-367; Santa Cruz Biotechnology,
CA, USA), respectively, and incubated overnight at 4∘C;
then the corresponding horseradish peroxidase-conjugated
secondary antibody (1 : 10,000) was incubated for 2 h. Protein
expressions were visualized by the ECL system (Perce, Rock-
ford, IL) and analyzed using Quantity One 4.6.1 software of
the ChemiDoc XRS system (Bio-Rad Laboratories, Hercules,
CA, USA).
2.10. Statistical Analyses. All values are expressed as mean ±
SE. Comparisons across the three groups were performed
using one-way analysis of variance (ANOVA) followed by
Tukey test to determine significant differences between two
groups using Prism version 5 (GraphPad Inc., San Diego,
CA). Coefficient of correlation was performed to evaluate
whether there is any correlation between serum levels of
resistin and changes of HOMA-IR and proinflammatory
cytokines (TNF-𝛼 and IL-6). 𝑃 value <0.05 was considered
statistically significant.
3. Results
3.1. Decreased Resistin Expression and Secretion by Antiresistin
RNAOligonucleotide. By a total of 14weeks ofHFDexposure,
C57BL/6 mice increased epididymal fat mass and developed
metabolic syndrome with the elevated serum AST and ALT
levels when compared with chow fed mice (Table 2). In
association with these metabolic changes, ELISA analyses
revealed that serum resistin levels were significantly higher
in HFD control mice than chow fed mice (Table 2, 𝑃 <
0.01). Expression of resistin mRNA was increased by 139.6%
in adipose tissue and 46.6% in the liver of HFD mice
compared with chow fed mice (Figures 1(a) and 1(b), 𝑃 <
0.01 and 0.01, resp.). qRT-PCR analysis also revealed that
the increased expression of resistin mRNA was markedly
blocked by antiresistin RNA oligo in adipose tissue and liver
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Table 1: The primer sequences.
Gene Nucleotide Sequence (5󸀠 to 3󸀠) Product size (bp) Accession number
Retn (resistin) Sense AGA CTG CTG GCC TTC TGG GC 194 AF323080.1
Antisense TTT CCT TTT CTT CCT TG
Tnf (TNF-𝛼) Sense ATGGCCTCCCTCTCATCAGT 97 NM 013693.3
Antisense TTTGCTACGACGTGGGCTAC
Il6 (IL-6) Sense GAT GCT ACC AAA CTG GAT ATA ATC 247 NM 031168.1
Antisense GGT CCT TAG CCA CTC CTT CTG TG
Pck1 (PEPCK) Sense TGCGGATCATGACTCGGATG 126 NM 011044
Antisense AGGCCCAGTTGTTGACCAAA
Scebp1 (SREBP-1c) Sense CGGCTCTGGAACAGACACTG 185 NM 011480.3
Antisense CTCAGGAGAGTTGGCACCTG
Adipoq (adiponectin) Sense GGAACTTGTGCAGGTTGGATG 171 NM 009605.4
Antisense CCCTTCAGCTCCTGTCATTCC
Lep (leptin) Sense CACCAGGATCAATGACATTTCACA 71 NM 008493.3
Antisense TGAAGTCCAAGCCAGTGACC
Actb (𝛽-actin) Sense GTA CCA CTG GCA TCG TGA TGG ACT 323 NM 007393
Antisense CCG CTC ATT GCC AAT GGT GAT
Table 2: Effects of antiresistin RNA oligo on body weight, metabolic parameters, and hepatic enzymes.
Paradigm parameter Chow HF-Con-oligo HF-Res-oligo
After treatment Bwt (g) 28.5 ± 0.9 32.8 ± 1.2a 32.1 ± 1.7d
Epididymal fat (g/100 g Bwt) 1.58 ± 0.05 3.3 ± 0.12b 2.62 ± 0.32ad
Serum glucose (mM) 6.70 ± 0.75 9.59 ± 0.72a 7.22 ± 0.30d
Serum insulin (pg/mL) 528 ± 150 689 ± 121a 503 ± 164d
HOMA-IR 22.8 ± 1.9 50.1 ± 6.4b 27.5 ± 6.2d
Serum cholesterol (mM) 3.90 ± 0.09 6.87 ± 0.21b 4.95 ± 0.37d
Serum triglyceride (mM) 0.63 ± 0.01 0.98 ± 0.02b 0.79 ± 0.04d
Serum NEFA (mM) 0.78 ± 0.16 1.03 ± 0.08a 0.83 ± 0.03d
Serum ALT (U/L) 29.9 ± 0.6 89.6 ± 9.5b 52.1 ± 10.3d
Serum AST (U/L) 32.4 ± 7.9 199.8 ± 21.7c 65.8 ± 11.7f
Serum resistin (pg/mL) 513 ± 36 668 ± 35b 472 ± 19e
Mice were fed standard chow and high-fat diet for 10 weeks and then with 4-week i.p injection (3 times/week) of saline (Chow, 5mL/kg of body weight),
scrambled control oligo (HF-Con-oligo 25mg/kg of body weight), or antiresistin RNA oligo (HF-Res-oligo, 25mg/kg of body weight). Metabolic parameters
are represented as mean ± SEM (𝑛 = 10 each group) after 4 weeks’ treatment. Bwt: body weight; HOMA-IR: homeostatic model assessment-insulin resistance;
TG: triglycerides; NEFAs: nonesterified fatty acids; AST: aspartate aminotransferase; ALT: alanine aminotransferase. a𝑃 < 0.05, b𝑃 < 0.01, and c𝑃 < 0.001
HF-Con-oligo group versus chow fed mice; d𝑃 < 0.05, e𝑃 < 0.01, and f𝑃 < 0.001 versus HF-Con-oligo mice.
(Figures 1(a) and 1(b), 𝑃 < 0.01 and 𝑃 < 0.05; HF-Res-oligo
group versus HF-Con-oligo group). HFD increased resistin
protein expression by 190.3% in adipose tissue and 73.3%
in the liver (Figures 1(c) and 1(d), HFD-control oligo mice
versus chow group,𝑃 < 0.01) and the 4 weeks’ treatment with
antiresistin oligo prevented overexpression of resistin protein
in adipose and liver tissues (Figures 1(c) and 1(d), 𝑃 < 0.01).
These results indicate that the synthetic RNA oligo
effectively blocked resistin gene expression and reduced
its translation into protein, which resulted in a decreased
secretion of resistin into the circulation (Table 2, 𝑃 < 0.01)
in antiresistin oligo treated mice.
3.2. Effects of Antiresistin RNA Oligo on Body Weight, Meta-
bolic Parameters, and Hepatic Enzymes. Table 2 shows that
the body weight of HFD fed mice was significantly higher
than chow fed mice (𝑃 < 0.05). The body weight gain was
slightly lower in antiresistin treated group than the control
oligo group but there was no statistical significance. However,
the weight of epididymal fat mass was significantly lower
in antiresistin oligo treated mice when compared with the
Con-oligo group (𝑃 < 0.05). HFD feeding significantly
increased fasting serum glucose level (𝑃 < 0.05 HFD versus
chow fed mice) associated with 30.7% elevation of serum
insulin levels (𝑃 < 0.05), indicating insulin resistance.
Antiresistin oligo treatment significantly decreased fasting
serum glucose (Table 2, Res-oligo versus C-oligo group, 𝑃 <
0.05) associated with improved insulin resistance, evidenced
by a reduction of fasting serum insulin levels (𝑃 < 0.01) and
reduced HOMA-IR values (Table 2, 𝑃 < 0.05). Antiresistin































































































































Figure 1: Effects of synthetic RNA oligo on resistin expression and secretion. Immunoblots and quantitative analysis of resistin protein in
adipose tissue (a) and in the liver (b); relative mRNA expression was quantified by qRT-PCR in adipose tissue (c) and in the liver (d). Data
are mean ± SE from 10 mice each group. b𝑃 < 0.01 versus chow fed mice; e𝑃 < 0.01 versus HF-Con-oligo mice.
oligo also significantly reduced the elevated serum levels of
cholesterol, TG, andNEFAs levels by 27.9%, 20.1%, and 19.4%,
respectively, (all 𝑃 < 0.05) when compared with the HF-
Con oligo group. Serum hepatic enzyme (AST and ALT)
levels in HFD fed mice were increased by 3.0- and 6.2-fold,
respectively, when compared with chow fed mice (Table 2,
both 0.001). Antiresistin oligo treatment significantly atten-
uated the elevated AST and ALT values (𝑃 < 0.05 and 𝑃 <
0.001, resp.) when compared with control oligo treated mice
(Table 2).
3.3. Effect of Antiresistin RNA Oligo on i.p.GTT. Impaired
glucose tolerance was induced by HFD feeding, showing
significantly increased AUC of glucose profile values by
32.7% over the entire i.p.GTT (Figures 2(a) and 2(b), AUG
1757 ± 61 versus 2610 ± 179mM⋅min, 𝑃 < 0.01). Blood
glucose disposal was significantly faster in antiresistin RNA
oligo treated mice, evidenced by 29.7% reduction of AUC
values compared with the HF-control oligo group (Figure 2,
𝑃 < 0.05). The results of i.p.GTT together with HOMA-
IR (Table 2) indicate that antiresistin RNA oligo improved
whole-body insulin resistance in HFD mice. Reduction of
serum levels of resistin was positively correlated to the
enhanced insulin sensitivity in antiresistin RNA oligo treated
mice (Figure 2(c), 𝑃 < 0.001).
3.4. Effect of Antiresistin RNA Oligo on Lipid Deposition in
the Liver and Hepatic Steatosis. The photomicrographs of
the HE stain showed that the majority of the hepatocytes of
HFDmicewere distended by fat accumulation in comparison
to the chow group (Figure 3(a)). Analysis of blindly scored
HE-stained sections showed a statistically significant increase
in lipid-laden hepatocytes in the liver tissue of control
oligo treated mice (Figure 3(c), 𝑃 < 0.05 versus chow fed
mice). The treatment with antiresistin oligo decreased the
grade of hepatic steatosis compared with control oligo group
(Figures 3(a) and 3(c)), indicating that antiresistin RNAoligo
greatly prevented lipid infiltrations and hepatic steatosis. Oil


































































Figure 2: Effects of antiresistin RNA oligo on intraperitoneal i.p. glucose tolerance test. (a) Blood glucose response to i.p. glucose injection,
(b) area under the curves (AUC) of glucose profile values in chow fedmice and HFD fedmice treated with a control oligo or antiresistin RNA
oligo, and (c) the correlations between serum levels of resistin and whole-body insulin sensitivity index (HOMA-IR). Data are mean ± SE
(𝑛 = 10 each group). b𝑃 < 0.01 versus chow fed mice; e𝑃 < 0.05 versus HF-Con-oligo mice.
Red O staining exhibited many lipid droplets in the liver
sections of HFD control mice (Figure 3(b)), whereas few
or no lipid droplets were seen in the liver sections from
the chow and antiresistin RNA oligo treated HFD mice
(Figure 3(b)). Consistent with histological appearance, the
hepatic TG levels were significantly higher in HFD fed mice
than those in chow fed group (Figure 3(d), 11.3 ± 0.9 versus
7.4 ± 0.9 𝜇M/g, 𝑃 < 0.05). This increase was significantly
prevented by antiresistin RNA oligo treatment (Figure 3(d),
𝑃 < 0.05 versus Con-oligo group). Together with normalized
serum AST and ALT levels (Table 2), these findings indicate
that inhibitions of resistin expression and secretion with
RNA oligo can improve HFD-induced pathological changes
in NAFLD.
3.5. Effects of Antiresistin RNA Oligo on Serum Proinflam-
matory Cytokines, Leptin, and Adiponectin. Figure 4 shows
significantly increased serum TNF-𝛼, IL-6, and leptin asso-
ciated with 55.6% reduction of adiponectin in HF-control
mice as compared with the chow group (𝑃 < 0.05), whereas
antiresistin oligo treatment markedly decreased the elevation
of TNF-𝛼 and IL-6 (Figures 4(a) and 4(b), both 𝑃 < 0.05).
There were neither significant alterations of circulating IL-10
and IFN𝛾 levels by HFD feeding nor changes of serum leptin
level by antiresistin oligo treatment (Figures 4(c), 4(d), and
4(e)). Interestingly, the levels of serum adiponectin were the
lowest in the HF-control group and increased by 36.3% in
antiresistin oligo treated group (Figure 4(f), 𝑃 < 0.05 versus
HF-control).
According to the fact that resistin is mainly secreted
by macrophages in humans we hypothesised that resistin
implicates NAFLD through upregulating secretion of proin-
flammatory cytokines from adipose tissue. The illustration
of the relationship between circulating levels of resistin and
proinflammatory cytokines will help to understand underly-
ing mechanism by which antiresistin RNA oligo improved
NAFLD pathology. Figures 4(g) and 4(h) showed reduced
serum resistin was correlatively associated with decreased
serum levels of TNF-𝛼 and IL-6 (both 𝑃 < 0.001).
3.6. Effects of Antiresistin RNA Oligo on mRNA Expres-
sions of Proinflammatory Cytokines, PEPCK and SREBP-1c.
Figure 5(a) shows that mRNA expressions of TNF-𝛼, IL-
6, and leptin in adipose tissue were significantly higher in
the HFD control mice as compared with chow fed mice.
These results were consistent with the measurements in the
circulation, indicating that HFD feeding induced TNF-𝛼, IL-
6, and leptin gene expression and secretion. Inhibition of
resistin with RNA oligo was associated with reduced mRNA
expressions of TNF-𝛼, IL-6, and increased adiponectin
(Figure 5(a), all 𝑃 < 0.05) but antiresistin oligo did not affect
leptin gene expression (Figure 5(a)). In the liver, TNF-𝛼, IL-6,
and mRNA also significantly increased by HFD feeding and
decreased by antiresistin oligo treatment (Figure 5(b)). To
clarify whether resistin implicates hepatic glucose production
and hepatic fatty acid synthesis, the gene expressions involved
in hepatic gluconeogenesis and lipogenesis pathways were
detected. mRNA expression of PEPCK and SREBP-1c was
significantly increased in HFD control group as compared
with chow fed mice. The mRNA of PEPCK in antiresistin
oligo treated mice was significantly lower than HF-control
group (Figure 5(b), 𝑃 < 0.05). SREBP-1c mRNA was reduced
by 68.5% in antiresistin oligo treatedmice compared with the
HFD control (𝑃 < 0.01).
3.7. Effects of Antiresistin RNA Oligo on Expressions of PEPCK
and SREBP-1c in the Liver. To clarify whether inhibition
of resistin mRNA alters protein expression of PEPCK and




















































Figure 3: Effects of antiresistin RNA oligo on lipid deposition in the liver and hepatic steatosis. Sections of liver from chow fed mice and
HFD fed mice treated with a control oligo or antiresistin oligo were stained with Hematoxylin/Eosin (a). Bottom left corner shows enlarged
views of inset image.The arrows show hepatic steatosis and Oil Red O (b) to visualize lipid droplets.The hepatic steatosis grade was based on
the percentage of steatotic hepatocytes in the H&E-stained liver sections (c). Hepatic tissue triglyceride levels (d) in all groups of mice. Data
are mean ± SE. 𝑛 = 10. b𝑃 < 0.01 versus chow fed mice; d𝑃 < 0.05 versus HF-Con-oligo mice.
SREBP-1c both molecules in the liver were detected by
immunoblotting. When compared with chow group, chronic
HFD feeding led to 50% increase in PEPCK protein content
in the liver (Figure 6(a), 𝑃 < 0.01). Antiresistin oligo
treatment significantly decreased PEPCK protein expression
compared to control oligo treatment (Figure 6(a), 𝑃 < 0.05).
HFD feeding also led to 75% increase in SREBP-1c protein
expression in the liver (Figure 6(b), 𝑃 < 0.01). Antiresistin
oligo treatment reversed overexpression of SREBP-1c protein
compared to control oligo treatment (Figure 6(b), 𝑃 < 0.01).
4. Discussion
Resistin has been recognised as an adipocytokine positively
correlated with insulin resistance and type 2 diabetes and
is predictive of cardiovascular disease [15, 16]. However, the
role of resistin in obesity associated with fatty liver disease
remains controversial [17–19]. In the present study, we aimed
to (1) identify whether the development of NAFLD induced
by HFD feeding in mice is associated with overexpression
of resistin mRNA and protein in adipose tissue and the
liver; (2) observe whether inhibition of resistin expression
with synthetic RNA oligo attenuates metabolic and histolog-
ical abnormalities in NAFLD; and (3) clarify whether and
which inflammatory cytokines and signalling molecules are
involved in resistin-mediated hepatic insulin resistance and
NAFLD.
This study discovered that, after a total of 14weeks ofHFD
exposure, C57BL/6 mice developed abdominal obesity asso-
ciatedwith hyperlipidaemia, hyperinsulinemia, and impaired







































































































































































Figure 4: Effects of antiresistin RNA oligo on circulating proinflammatory cytokines, leptin, and adiponectin. Serum TNF-𝛼, IL-6, IL-10,
and IFN𝛾 (a–d) and leptin and adiponectin levels (e-f) were determined in chow fed mice and HFD fed mice treated with a control oligo or
antiresistin oligo. The correlations between the differences of serum resistin and both the differences of serum TNF-𝛼 (g) and IL-6 (h). Data
are mean ± SE (𝑛 = 10). a𝑃 < 0.05 and b𝑃 < 0.01 versus chow fed mice; d𝑃 < 0.05 versus HFD-Con-oligo mice.
GTT. Resistin mRNA and protein expressions were markedly
increased in white adipose tissue of HFD control mice,
which led to elevated circulating resistin levels. The previous
study showed that elevated plasma resistin is associated
with hepatic insulin resistance induced by 3 weeks’ HFD
feeding in mice and that treatment with antisense resistin
suppressed hepatic glucose production [23]. However, that
overexpression of resistin links to NAFLD has not been
examined [23]. Our study showed that, on HFD exposure for
14weeks, C57BL/6mice developedmoderate hepatic steatosis
with elevated serum AST and ALT, indicating pathological
changes of NAFLD in HFD mice. Interestingly, resistin
mRNA and protein expressions were also significantly higher
in liver tissue ofHFDmice, suggesting that resistin is involved
in HFD-induced NAFLD. Because resistin in rodents is
primarily expressed by adipocytes the induced expression of
resistin protein and mRNA in the liver is possibly secondary
to hepatic fat accumulation in HFD mice. Furthermore, our
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(b) In liver tissue
Figure 5: Effects of antiresistin RNA oligo on mRNA expression. (a) TNF-𝛼, IL-6, leptin, and adiponectin mRNA expression in adipose
tissue; (b) hepatic mRNA expression of TNF-𝛼, IL-6, PEPCK, and SREBP-1c in chow fed mice and HFD fed mice treated with a control oligo
or antiresistin oligo. Data are mean ± SE (𝑛 = 10). a𝑃 < 0.05 and b𝑃 < 0.01 versus chow fed mice; d𝑃 < 0.05 versus HFD-Con-oligo mice.















































































Figure 6: Effects of antiresistin RNA oligo on PEPCK and SREBP1c expression in the liver. Immunoblots and quantitative analysis of PEPCK
(a) and SREBP-1c (b) protein in liver tissue of chow fed mice and HFD fed mice treated with a control oligo or antiresistin oligo. Data are
mean ± SE (𝑛 = 10). b𝑃 < 0.01 versus chow fed mice; d𝑃 < 0.05 and e𝑃 < 0.01 versus HFD-Con-oligo mice.
study found that reduction of resistin with RNA oligo treat-
ment ameliorated hyperinsulinemia and improved impaired
GTT. Antiresistin oligo treatment also improved hyper-
lipidaemia and hepatic TG accumulation and normalized
hepatic enzymes and the histological spectrum of hepatic
steatosis in HFDmice.TheNEFA levels in antiresistin treated
mice were significantly reduced, consequently diminishing
the influx of free FFAs to the liver, and thus attenuated FFAs-
induced lipotoxicity. FFAs have direct hepatotoxicity through
the induction of an endoplasmic reticulum stress response
and subsequent activation of the mitochondrial pathway of
cell death [26]. Lipotoxicity is a key pathogenic process in
NAFLD, and it correlates with progressive inflammation and
fibrosis [27].
Several lines of studies have shown a very strong and
consistent association between resistin and inflammatory
diseases in humans [8, 24, 25]. The mechanisms of NAFLD
are closely linked to adipose dysfunction which increases
secretion of proinflammatory cytokines, including TNF-𝛼,
IL-6, transforming growth factor-𝛽, and retinol binding
protein-4 [8, 22, 27–29]. TNF-𝛼 has been implicated in
insulin resistance and liver fibrosis as well as advanced stages
of NAFLD in humans [28]. IL-6, as a proinflammatory
cytokine, has been proposed as a potential mediator leading
to NAFLD [29]. In this study, we observed that elevated
circulating resistin was associated with increased serum
TNF-𝛼, IL-6, and leptin; on the other hand, adiponectin was
decreased in HFD fed mice. The elevated levels of serum
resistin, TNF-𝛼, IL-6, and hepatic enzymes suggest that
resistin may contribute to NAFLD, at least in part, through
upregulating systemic and hepatic inflammation.
The key finding of this study is that treatment with
synthetic RNA oligo significantly reduced adipose mass and
attenuated overexpression of resistin along with normalized
serum TNF-𝛼 and IL-6 and enhanced adiponectin. Conse-
quently, glucose intolerance and histopathological changes in
the liver were improved by antiresistin RNA oligo treatment.
Thus, it is highly likely that the events in the liver are due
to the primary effects of the intervention on the adipose
tissue events. A previous study showed that loss of resistin
prevented hepatic steatosis is related to leptin deficiency [30].
In our study, reduced resistin expression and secession by
RNA oligo neither significantly affected serum leptin levels
nor altered leptin mRNA expression in adipose tissue. This
study provided evidence to support the notion that resistin
plays an important role in the pathogenesis of NAFLD but its
effect is independent of the leptin pathway. Lowering resistin
by RNA oligo with reduction of circulating TNF-𝛼 and IL-
6 might provide a new insight into managing inflammation-
mediated diseases, such as NAFLD, type 2 diabetes, and
cardiovascular disease.
Our previous study showed that HFD-induced NAFLD
in rats is associated with decreased insulin activation of
glycogen synthase and increased gluconeogenesis [31], which,
in turn, exacerbates hyperglycemia. In this study, antiresistin
oligo treatment attenuated the elevated serum glucose, possi-
bly through regulating hepatic gluconeogenesis and decreas-
ing glucose production. Liver gluconeogenesis is driven by
the availability of gluconeogenic substrates and the activity
of PEPCK and glucose 6-phosphatase [32]. To understand
whether antiresistin oligo also influences enzymes involved
in gluconeogenesis, the expression of hepatic PEPCK was
detected by qRT-PCR and Western blotting in liver tissues.
We observed that the elevated serum level of resistin was
associated with the expression of PEPCK in the liver of
HFD mice. Furthermore, we found that inhibition of resistin
with RNA oligo decreased PEPCK expression. Antiresistin
RNA oligo treatment significantly reduced serum glucose
level associated with downregulation of PEPECK expression,
suggesting that inhibition of resistin may be a potential ther-
apy for hyperglycemia through downregulation of hepatic
PEPCK.
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The hallmark of NAFLD is the presence of ectopic fat in
the hepatocytes.The underlyingmechanism of this patholog-
ical fat deposition, mainly triglycerides [33], is involved in an
imbalance between lipid availability (from circulating lipid
uptake or de novo lipogenesis) and lipid disposal (via FFA
oxidation or triglyceride-rich lipoprotein secretion) which
eventually triggers lipid peroxidative stress and hepatic injury
[34]. In this study, HFD feeding caused hyperlipidemia asso-
ciated with markedly elevated levels of serum AST and ALT,
indicating hepatocytes injury and hepatic overproduction
of lipids. The rate of hepatic lipogenesis is controlled by
sterol regulatory element-binding proteins (SREBPs) which
enhance transcription of genes encoding enzymes of triglyc-
erides and fatty acid biosynthesis and uptake [35]. SREBPs
have three subtypes, SREBP-1a, SREBP-1c, and SREBP-2.
Among them, SREBP-1c is most highly expressed in brown
fat, followed by the liver [36]. Previous study showed that
SREBP-1c as a key transcription factor regulating the gene
expression of key enzymes implicated in lipogenesis in
the liver is experimentally connected to NAFLD [37]. To
understand the mechanism underlying reduced hepatic lipid
accumulation by antiresistin RNAoligowemeasured SREBP-
1c mRNA and protein expression in liver tissues of HFDmice
with or without antiresistin RNA oligo treatment.We showed
that elevated serum resistin was positively related to SREBP-
1c mRNA and protein expression in the liver of HFD mice.
Inhibition of resistin with RNA oligo was associated with
markedly decreased SREBP-1c expression, which is likely to
reduce hepatic triglyceride biosynthesis (de novo lipogenesis)
and outflux. Conversely, previous study showed that increase
in cellular neutral lipid content induced by human resistin is
mediated through the induction of the cellular SREBP-1 and
SREBP-2 lipogenic pathways [38]. A recent study reported
that SREBP-1 expression and transcriptional activity were
not affected in antiresistin siRNA 3T3-L1 cells [39]. The
different findings between the current in vivo study and
previous in vitro study by Ikeda et al. may be due to SREBP-
1c gene selectively expressed in the liver and relevantly low
level of SREBP-1 expression in 3T3-L1 cells. Together with
increased lipid content associated overexpression of resistin
and SREBP-1c in HFD mice, this study demonstrated that
resistin promotes hepatic lipogenesis and hepatic steatosis
through, at least in part, upregulating SREBP-1c. Inhibition of
resistin may indirectly control hepatic lipogenesis pathway.
5. Conclusions
This study demonstrated that (1) downregulation of resistin
expression in adipose tissue and the liver with decreased
circulating resistin levels normalizedHFD-induced hyperlip-
idaemia and hyperglycemia; (2) reduction of elevated serum
resistin levels by antiresistin RNA oligo was associated with
a reduction of circulating TNF-𝛼 and IL-6 but with no
influence on serum leptin, indicating that resistin-mediated
hepatic steatosis occurs through upregulation of inflamma-
tion independent of the leptin pathway; (3) antiresistin oligo
may be capable of regulating gluconeogenesis and lipogenesis
in the liver through downregulation of hepatic PEPCK and
SREBP-1c expression. The effect of antiresistin RNA oligo in
mice may not be directly translated to clinical study because
the murine resistin protein has only 59% of similarity to
human one [40, 41]. Our findings that inhibition of resistin
with antisense RNA oligo ameliorated metabolic and histo-
logical abnormalities in animal model of NAFLD highlighted
the role of resistin in pathogenesis of NAFLD. This study
also demonstrated a correlative relationship between resistin
and TNF-𝛼 as well as IL-6, suggesting the proinflammatory
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HFD: High-fat diet
ILs: Interleukins
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SREBP-1c: Sterol regulatory element-binding protein-1c
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